Nidogen-1/Entactin Antibody (302117) [Alexa Fluor® 488]

• Reactivity: Hu
• Applications: WB, IHC, ELISA(Cap), ELISA(Det), ICC/IF
• Clone: 302117
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor 488

Nidogen-1/Entactin Antibody (302117) [Alexa Fluor® 488] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human Nidogen‑1/Entactin
  Leu29-Lys1114 (Gln1113Arg)
  Accession # AAH45606.1
• Specificity: Detects human Nidogen‑1/Entactin in ELISAs and Western blots. In direct ELISAs and Western blots, no cross-reactivity with recombinant human Nidogen-2 is observed.
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified

Applications/Dilutions

• Dilutions:
  • ELISA Capture (Matched Antibody Pair)
  • ELISA Detection (Matched Antibody Pair)
  • Immunocytochemistry
  • Immunohistochemistry
  • Western Blot

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Nidogen-1/Entactin Antibody (302117) [Alexa Fluor® 488]

• enactin
• Entactin
• Entactin-1
• NID1
• NID-1
• NIDentactin
• nidogen (enactin)
• nidogen 1
• Nidogen1
• Nidogen-1

Background

Nidogen-1 (also entactin) is a 150 kDa, secreted, monomeric glycoprotein that serves as a major linking component of basement membranes (1-4). It is synthesized as a 1247 amino acid (aa) precursor with a 28 aa signal sequence and a 1219 aa mature protein. The molecule is modular in structure with five distinct regions. There are three globular domains (G1-3) separated by a mucin region and an extended rod-shaped segment (5-7). The N-terminal globular domain (G1) is 200 aa in length and seemingly unrelated to any known motif (8). The mucin region is nearly 160 aa in length and presumably O-glycosylated (2, 8). G2 and G3 are both approximately 300 aa in length. G2 is described as a Nidogen ( beta -barrel) domain, while C-terminal G3 assumes a beta -propeller configuration (1). The 250 aa rod-shaped segment has multiple EGF-like motifs and two thyroglobulin type 1 domains. Functionally, G1 is reported to bind type IV collagen (2, 7). The mucin region contains a short peptide that ligates alpha ₃ beta ₁ integrins (9, 10). G2 interacts with perlecan, and an RGD motif in the rod-shaped segment serves as a binding site for alpha _v beta ₃ integrins (9, 10). Finally, G3 is associated with laminin binding (2, 7). As a full-length molecule, the multiple extracellular matrix-binding sites of Nidogen-1 are well positioned to serve as anchor sites for basement membrane molecules. Nidogen-1 also undergoes proteolytic processing by at least two MMPs, MMP-7 and MMP-19 (10, 11). While this destroys the integrity of Nidogen-associated matrices, it also generates peptide fragments that are capable of inducing neutrophil chemotaxis and phagocytosis (10). Nidogen-2 is related to Nidogen-1 (≈ 50% aa identity) and shares many of the same adhesive properties as Nidogen-1 (12). Both bind perlecan plus collagens I and IV. Nidogen‑2, however, does not bind fibulin-1 or 2, and shows only modest interaction with laminin. Thus, although coexpressed, Nidogen-2 serves as only a partial substitute for Nidogen-1 (2, 12). Human Nidogen-1 shares 85% aa sequence identity with both mouse and rat Nidogen-1, and 88% aa sequence identity with canine Nidogen-1.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.